title: The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia.
abstract: The US National Institute of Mental Health supported an initiative to facilitate the development of pharmacological agents for enhancing neurocognition in patients with schizophrenia. This has been accomplished through a consensus-building process that has included representatives from academia, the pharmaceutical industry, and government. The group has addressed obstacles to drug development that include (i) the lack of a well-accepted instrument for measuring neurocognition in clinical trials; (ii) the lack of a consensus on the best molecular target or targets for drug development; (iii) the lack of a consensus regarding the optimal trial design for either comedication that improves cognition when added to an antipsychotic or a broad spectrum agent that improves cognition and treats psychosis; and (iv) the approaches of regulatory agencies such as the US Food and Drug Administration to approving and labeling a new agent.
authors.affiliation: Semel Institute of Neuroscience, University of California at Los Angeles, Calif, USA. marder@ucla.edu
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Marder
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D006293:Health Promotion; D006801:Humans; D009315:National Institute of Mental Health (U.S.); D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014481:United States
chemical_list: D014150:Antipsychotic Agents